Drug intelligence / Profile preview

PNB-003

Development stage: Preclinical
Lead developer: Phage Nova Bio

Overview

PNB-003 is a drug candidate initially developed by PhageNova Bio. It is currently in the preclinical stage of development and is being investigated for use in endocrinology and metabolic therapeutic areas. Specific details regarding its mechanism of action, molecular target, or precise indication have not been disclosed publicly as of June 2025[1].

Beyond the preview

Go deeper on PNB-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNB-003.

Explore the full profile